DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center – WO66-G609
Silver Spring, MD 20993-0002

March 25, 2015

Davol Incorporated, Subsidiary of C. R. Bard Incorporated
Ms. Mariya Buharin
Regulatory Affairs Specialist
100 Crossings Boulevard
Warwick, Rhode Island 02886

Re: K142706
Trade/Device Name: Modified ONFLEX Mesh
Regulation Number: 21 CFR 878.3300
Regulation Name: Surgical mesh
Regulatory Class: Class II
Product Code: FTL
Dated: February 4, 2015
Received: February 5, 2015

Dear Ms. Buharin:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Jennifer R. Stevenson -S

For Binita S. Ashar, M.D., M.B.A., F.A.C.S.
Director
Division of Surgical Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120
Expiration Date: January 31, 2017
See PRA Statement below.

510(k) Number *(if known)*
K142706

Device Name
Modified ONFLEX Mesh

Indications for Use *(Describe)*
The Modified ONFLEX Mesh is indicated for use in the reinforcement of soft tissue where weakness exists, such as in the repair of inguinal hernias.

Type of Use *(Select one or both, as applicable)*

☒ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(K) SUMMARY

This 510(k) Summary is provided per the requirements of section 21 CFR 807.92.

I. Submitter

Submitter's Name:	Davol, Inc., Subsidiary of C. R. Bard, Inc.
Contact Person:	Mariya Buharin Regulatory Affairs Specialist
Address:	100 Crossings Boulevard Warwick, RI 02886
Telephone:	(401) 825-8729
Fax:	(401) 825-8765
Email:	marie.buharin@crbard.com
Date prepared:	March 19th, 2015

II. Device

Trade Name:	Modified ONFLEX™ Mesh
Common/Usual Name:	- Surgical Mesh
Classification Name:	- Mesh, Surgical, Polymeric (21 CFR § 878.3300)
Regulatory Class:	- Class II
Product Code:	- FTL

III. Predicate Devices

- Bard® 3DMax™ Light Mesh
  - K091659 (Davol, Inc.), FDA cleared on 08/08/2009
- Bard® Ventrio™ Hernia Patch,
  - K081777 (Davol, Inc.), FDA cleared on 09/29/2008
  - K100229 (Davol, Inc.), FDA cleared on 04/21/2010
- Bard® Modified Kugel™ Hernia Patch
  - K963141 (Davol, Inc.), FDA cleared on 10/11/1996

No reference devices were used in this submission.

IV. Device Description

The proposed Modified ONFLEX™ Mesh is a self-expanding, non-absorbable, sterile (Ethylene Oxide) prosthesis, made from monofilament polypropylene mesh and has a lightweight large pore design. This construction allows a prompt fibroblastic response through the interstices of the mesh as observed in a preclinical model, which may not correlate to performance in humans. The Modified ONFLEX™ Mesh has an anatomical shape designed to cover potential defect areas.

The Modified ONFLEX™ Mesh also contains two pockets to facilitate insertion and positioning of the device. The positioning pockets are located on the larger medical apex of the mesh and the lateral apex of the mesh. In addition to the pocket, the mesh also contains straps to facilitate

positioning and fixation of the device. The Modified ONFLEX™ Mesh comes packaged with an onlay which is available in one size and is optional based on surgeon preference.

The proposed device contains SorbaFlex™ Memory Technology comprised of an absorbable PDO monofilament which forms an interrupted ring. SorbaFlex™ Memory Technology provides memory and stability to the device, facilitating ease of initial insertion and proper placement of the device. The PDO monofilament is folded and welded onto itself at the ends. The interrupted ring provides memory and stability to the device, facilitating ease of initial insertion and proper placement of the device. The PDO monofilament fully degrades by means of hydrolysis *in vivo* in 6 – 8 months. The PDO monofilament is dyed violet by adding D & C Violet No. 2. The interrupted ring is placed within a mesh tube constructed from a knitted polypropylene monofilament. The purpose of the mesh tube is to contain the interrupted recoil ring during the degradation process. The interrupted ring, contained in the mesh tube, is sewn between two layers of mesh with polytetrafluoroethylene (PTFE) monofilament.

The Modified ONFLEX™ Mesh is offered in two sizes: medium (0115610) and large (0115611). The proposed Modified ONFLEX™ Mesh is considered a tissue contacting permanent implant according to Blue Book Memorandum issued on May 1, 1995, Use of International Standard ISO-10993, "Biological Evaluation of Medical Devices, Part 1: Evaluation and Testing".

V. Indications for Use

The Modified ONFLEX™ Mesh is indicated for use in the reinforcement of soft tissue where weakness exists, such as in the repair of inguinal hernias.

VI. Comparison of Technological Characteristics with the Predicate Devices

The Modified ONFLEX™ Mesh has the same intended use and similar technological characteristics, as the currently marketed predicates 3DMax™ Light Mesh (K091659), Ventrio™ Hernia Patch (K081777/ K100229), and Modified Kugel™ Hernia Patch (K963141). The Modified ONFLEX™ Mesh and predicates 3DMax™ Light Mesh, Modified Kugel™ Hernia Patch and Ventrio™ Hernia Patch are intended for use in the reinforcement of soft tissue where weakness exists. The Modified ONFLEX™ Mesh combines the large pore knit construction, and anatomical shape of 3DMax™ Light Mesh, the strap and onlay features of Modified Kugel™ Hernia Patch and the SorbaFlex™ Memory Technology, mesh tube and pocket features of Ventrio™ Hernia Patch.

The Modified ONFLEX™ Mesh and the predicates, 3DMax™ Light Mesh, Ventrio™ Hernia Patch, and Modified Kugel™ Hernia Patch are constructed from polypropylene monofilament. The Modified ONFLEX™ Mesh has a similar large pore knit construction and anatomical shape as the predicate 3DMax™ Light Mesh. The perimeter of the polypropylene mesh on the Modified ONFLEX™ Mesh is heat sealed to form a smooth edge, similar to the predicate 3DMax Light Mesh.

The Modified ONFLEX™ Mesh utilizes a PDO monofilament ring mechanism similar to the Ventrio™ Hernia Patch. The Modified ONFLEX™ Mesh's ring is interrupted and folded to form a loop on each end whereas Ventrio™ Hernia Patch has an uninterrupted ring that is ultrasonically welded together. The Modified ONFLEX™ Mesh uses the same mesh tube to encompass the ring mechanism as the predicate Ventrio™ Hernia Patch. This mesh tube is the same material composition, polypropylene, as the mesh that is used to construct the other mesh

layers of the Modified ONFLEX™ Mesh. The PDO monofilament in the mesh tube is sewn between two layers of mesh with PTFE monofilament in both the Modified ONFLEX™ Mesh and the predicate Ventrio Hernia Patch. Additionally, Ventrio™ Hernia Patch contains a layer of expanded polytetrafluoroethylene (ePTFE) which contacts bowel or viscera when used for soft tissue repair in ventral hernia, to minimize tissue attachment to the mesh. The proposed Modified ONFLEX™ Mesh is designed to be used primarily in soft tissue repair in the inguinal canal, and thus does not contain such a design feature.

The Modified ONFLEX™ Mesh has two positioning pockets similar to the Modified Kugel™ Hernia Patch and predicate Ventrio™ Hernia Patch. The Modified ONFLEX™ Mesh has two pockets, on the larger medial apex of the mesh and the lateral apex of the mesh formed by the top layer of mesh. The Ventrio™ Hernia Patch has two positioning pockets formed by a slit in the top layer of the mesh. The Modified Kugel™ Hernia Patch has two pockets formed by a hole on the top layer of the mesh. Additionally, the Modified ONFLEX™ Mesh has two positioning straps and is packaged with an optional onlay similar to the Modified Kugel™ Hernia Patch.

Mechanical testing was performed consistent with FDA Guidance for the Preparation of a Premarket Notification Application for a Surgical Mesh, issued March 2, 1999, to verify that the Modified ONFLEX™ Mesh's performance characteristics are similar to that of the predicate devices.

VII. Performance Data

The following performance data are provided in support of the substantial equivalence determination. Testing was performed in accordance per "FDA Guidance for the Preparation of Premarket Notification for a Surgical Mesh."

Biocompatibility Testing

Biocompatibility testing was conducted in accordance with the FDA Blue Book Memorandum #G95-1 "Use of International Standard ISO-10993, 'Biological Evaluation of Medical Devices Part 1: Evaluation and Testing,'" May 1, 1995, and International Standard ISO 10993-1 "Biological Evaluation of Medical Devices − Part 1: Evaluation and Testing Within a Risk Management Process," as recognized by FDA.

Modified ONFLEX™ Mesh is considered a tissue contacting permanent implant. Therefore, the following tests are required and were leveraged from the predicate devices in support of this premarket notification:

- Cytotoxicity
- Sensitization
- Intracutaneous reactivity
- Acute systemic toxicity
- Subchronic toxicity
- Genotoxicity
- Implantation

Electrical safety and electromagnetic compatibility (EMC)

There are no electrical or metal components in the Modified ONFLEX™ Mesh; therefore the proposed device does not require EMC and Electrical Safety evaluation.

Software Verification and Validation Testing
The proposed Modified ONFLEX Mesh™ does not contain software.

Mechanical Testing

The following physical and performance characteristics were measured to compare the proposed Modified ONFLEX™ Mesh to the predicates 3DMax™ Light Mesh, Modified Kugel™ Hernia Patch and Ventrio Hernia Patch:

- Mesh weave characteristics
- Mesh thickness
- Mesh pore size
- Mesh density
- Mesh stiffness
- Ball burst strength
- Suture pullout strength
- Tear strength
- PDO monofilament tensile strength
- Strap Attachment Strength
- Simulated deployment test

Animal Study

In vivo and *in vitro* resorption studies were performed to characterize the mechanical strength and resorption of the PDO monofilament in the SorbaFlex™ Memory Technology and originally were provided in support of the Ventrio™ Hernia Patch via K081777. Since Modified ONFLEX™ Mesh contains the same PDO monofilament as the predicate Ventrio™ Hernia Patch these resorption studies have been adopted and provided in support of this Modified ONFLEX™ Mesh submission.

VIII. Conclusions

The test results provided in this submission demonstrate that the Modified ONFLEX™ Mesh is substantially equivalent to the predicates.